Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Drug development

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet medical need worldwide. The pathogenesis of AD involves various pathophysiological events, including the accumulation of amyloid and tau, neuro-inflammation, and neuronal injury. Clinical trials focusing on new drugs for AD were documented in 2020, but subsequent developments have emerged since then.

What this study adds

Evidence grade: Low

This is a narrative review. This update reviews Alzheimer drug trials from 2020 to 2023 and notes that the FDA approved aducanumab and lecanemab, both amyloid-targeting antibodies, ending nearly two decades without new Alzheimer drugs. It is a report on the trial landscape, not evidence that these drugs cure or prevent the disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Huang, L. K., Kuan, Y. C., Lin, H. W., & Hu, C. J. (2023). Clinical trials of new drugs for Alzheimer disease: a 2020-2023 update. Journal of biomedical science. https://doi.org/10.1186/s12929-023-00976-6

Vancouver

Huang LK, Kuan YC, Lin HW, Hu CJ. Clinical trials of new drugs for Alzheimer disease: a 2020-2023 update. Journal of biomedical science. 2023. doi:10.1186/s12929-023-00976-6. PMID: 37784171.

BibTeX

@article{huang2023-37784171,
  author  = {Huang, L. K. and Kuan, Y. C. and Lin, H. W. and Hu, C. J.},
  title   = {{Clinical trials of new drugs for Alzheimer disease: a 2020-2023 update}},
  journal = {Journal of biomedical science},
  year    = {2023},
  doi     = {10.1186/s12929-023-00976-6},
  pmid    = {37784171},
  url     = {https://doi.org/10.1186/s12929-023-00976-6}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This update reviews Alzheimer drug trials from 2020 to 2023 and notes that the FDA approved aducanumab and lecanemab, both amyloid-targeting antibodies, ending nearly two decades without new Alzheimer drugs. It is a report on the trial landscape, not evidence that these drugs cure or prevent the disease.

Study details

How this study scored 52/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 5 of 5; Impact for its field and year 5 of 6; Cited by studies here 2 of 6; Still being cited 4 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 52 of 100.52 of 100 points earned48 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of biomedical science)
Journal's citation record 2 / 4 Journal of Biomedical Science: journal h-index 151 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2023 — within 6 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 250 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 50.0 citations a year over 5 year(s) since 2023
Impact for its field and year 5 / 6 Cited 36.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 3 other studies in this library
Still being cited 4 / 4 Cited 245 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Chaur‐Jong Hu: h-index 48 (OpenAlex, whole career)
Institution's track record 1 / 3 National Taiwan University: institution h-index 752 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 37784171)
Free to read 2 / 2 Free to read
Total 52 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 23.

Later studies that cite this one

3 studies in the alzhub library list this one in their references.

Related studies in Drug development from nearby years

Also in Drug development

107 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.

Similar studies

More on Drug development

See all studies in Drug development →